Submission includes results of the pivotal DISSOLVE I and II studies NASP PDUFA date set for 27 June 2026 STOCKHOLM, Sept. 10, 2025 /PRNewswire/ — Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare diseases, today…
